Neurobiologist Paul Greengard Dies

The Nobel laureate revolutionized our understanding of how brain cells communicate.

Written byAshley Yeager
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

ABOVE: ROCKEFELLER UNIVERSITY, PIOTR REDLINKSKI

Nobel laureate Paul Greengard, a neurobiologist at Rockefeller University, died Saturday (April 13). He was 93.

Greengard is best known for his work showing that the brain not only communicates with electrical signals but also with chemicals such as dopamine. His studies investigating how cells respond to dopamine provided the evidence needed to develop antipsychotic drugs that regulate the strength of chemical signals in the brain, according to The New York Times.

“Paul was an iconic scientist whose extraordinary seven-decade career transformed our understanding of neuroscience,” Richard Lifton, Rockefeller’s president, says in a statement. “His discoveries laid out a new paradigm requiring the understanding of the biochemistry of nerve cells rather than simply their electrical activities. This work has had great impact. Today, abnormalities in signaling among neurons are recognized to underlie many neurologic and psychiatric disorders including Parkinson’s disease, schizophrenia, depression, attention deficit hyperactivity ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Ashley started at The Scientist in 2018. Before joining the staff, she worked as a freelance editor and writer, a writer at the Simons Foundation, and a web producer at Science News, among other positions. She holds a bachelor’s degree in journalism from the University of Tennessee, Knoxville, and a master’s degree in science writing from MIT. Ashley edits the Scientist to Watch and Profile sections of the magazine and writes news, features, and other stories for both online and print.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies